Search results
Results from the WOW.Com Content Network
Compared with certain other L-type calcium channel blockers (for example those of the phenylalkylamine class such as verapamil) that have significant action at the heart, the dihydropyridine calcium channel blockers lower blood pressure mainly by relaxing the smooth muscle of the blood vessel walls. [3]
Efonidipine is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel (ランデル). The drug blocks both T-type and L-type calcium channels. [1] Drug Controller General of India (DCGI) has approved the use of efonidipine in India. [2]
Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists [2] are a group of medications that disrupt the movement of calcium (Ca 2+) through calcium channels. [3] Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension.
1,4-Dihydropyridine (DHP) is an organic compound with the formula CH 2 (CH=CH) 2 NH. The parent compound is uncommon, [ 2 ] but derivatives of 1,4-dihydropyridine are important commercially and biologically.
Benidipine is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension). It is a triple L-, T-, and N-type calcium channel blocker. It is reno- and cardioprotective. It was patented in 1981 and approved for medical use in 1991. [1]
AHFS/Drugs.com: International Drug Names: Routes of administration: Oral: ATC code: C08CA11 ; ... Manidipine is a calcium channel blocker (dihydropyridine type) ...
Barnidipine is a pure S,S isomer, a lipophilic 1,4-dihydropyridine calcium channel blocker, which, like other compounds in the class, shows a high affinity for calcium channels, particularly the L-type slow channels of smooth muscle cells found in the vessel wall. [2]
Isradipine (tradenames DynaCirc, Prescal) is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. It was patented in 1978 and approved for medical use in 1989. [1]